

BIOGRAPHICAL SKETCH

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Clifton O. Bingham, III, M.D.	POSITION TITLE Assistant Professor of Medicine		
eRA COMMONS USER NAME			
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)			
INSTITUTION AND LOCATION	DEGREE (if applicable)	YEAR(s)	FIELD OF STUDY
Northwestern University, Evanston, IL	B.A.	1986	Neurobiol & Physiology
Columbia Univ, Coll Phys & Surgeons, NY, NY	M.D.	1990	Medicine

A. POSITIONS AND HONORS**Professional Experience**

1990-1991 Intern, Internal Medicine, Columbia-Presbyterian Medical Center, New York, NY
 1991-1993 Resident, Internal Medicine, Columbia-Presbyterian Medical Center, New York, NY
 1993-1996 Clinical Fellow Rheumatology, Brigham and Women's Hospital, Boston, MA
 1994-1996 Research Fellow, Dept. of Medicine, Harvard Medical School, Boston, MA
 1996-1998 Clinical Fellow Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, MA.
 1996-1999 Instructor in Medicine, Harvard Medical School, Boston, MA
 1996-1999 Associate Physician in Rheumatology, Brigham and Women's Hospital, Boston, MA
 1998-1999 Associate Physician in Allergy and Immunology, Massachusetts General Hospital and Brigham and Women's Hospital, Boston, MA
 1999-2004 Assistant Professor of Medicine, New York University School of Medicine, New York, NY
 1999-2001 Co-Director, Ambulatory Clinical Research Center, Hospital for Joint Diseases, New York, NY
 1999-2001 Director, Arthritis Clinic, Bellevue Hospital Center, New York, NY
 1999-2004 Attending Physician, NYU-Hospital for Joint Diseases, Bellevue Hospital Center, New York University Medical Center, New York, NY
 2001-2004 Consultant- Rheumatology, VA Medical Center, New York Campus, New York, NY
 2001-2004 Director, Ambulatory Clinical Research Center, Hospital for Joint Diseases, New York, NY
 2002-2004 Director, Seligman Center for Advanced Therapeutics, NYU-Hosp for Joint Dis, New York, NY
 2005-present Assistant Professor of Medicine, Johns Hopkins University, Baltimore, MD

Honors

National Merit Scholar, Northwestern University, 1983; Three Year B.A. Program, Northwestern University, 1983-1986; 1984; National Institutes of Mental Health, Fellowship in Community Psychiatry, NY State Psychiatric Institute, 1987; Outstanding Clinical Teaching, Columbia- Presbyterian Med. Center, 1990-1993; Rheumatology Fellows Reporter Program, 1993; Award for Center Excellence, Harvard-Pilgrim Health Plan, 1996; Arthritis Foundation Postdoctoral Fellowship, 1997-1999; President's Grant-in-Aid Award, 1998; American Academy of Allergy Asthma and Immunology, 1998; Goldstein Young Scholar Award, New York Chapter Arthritis Foundation, 2001-2004; Arthritis Investigator Award, National Arthritis Foundation, 2005-2006.

B. SELECTED PEER-REVIEWED PUBLICATIONS

1. Murakami M, Austen KF, Bingham CO III, Friend DS, Penrose JF, Arm JP. Interleukin-3 regulates development of the 5-lipoxygenase/ leukotriene C₄ synthase pathway in mouse mast cells. *J Biol Chem*, 1995; 270: 22653-6.
2. Murakami M, Bingham CO III, Matsumoto R, Austen KF, Arm JP. IgE-dependent activation of cytokine-primed mouse cultured mast cells induces a delayed phase of prostaglandin D₂ generation via prostaglandin endoperoxide synthase-2. *J Immunol*, 1995; 155: 4445-53.

3. Bingham CO III, Murakami M, Fujishima H, Hunt JH, Austen KF, Arm JP. A heparin-sensitive phospholipase A₂ and prostaglandin endoperoxide synthase-2 are functionally linked in the delayed phase of prostaglandin D₂ generation in mouse bone marrow-derived mast cells. *J Biol Chem*, 1996; 271: 25936-44.
4. Fujishima H, Sanchez R, Bingham CO III, Lam BK, Saperstein A, Bonventre JV, Austen KF, Arm JP. Cytosolic phospholipase A₂ is essential for both the immediate and the delayed phases of eicosanoid generation in mouse bone marrow-derived mast cells. *Proc Natl Acad Sci USA*, 1999; 96: 4803-7.
5. Shadick NA, Liang MH, Partridge AJ, Bingham CO III, Wright E, Fossel AH, Sheffer AL. The natural history of exercise-induced anaphylaxis: Survey results from a 10-year follow-up study. *J Allergy Clin Immunol*, 1999; 104: 123-7.
6. Bingham CO III, Fijneman RJA, Friend DS, Goddeau RP, Rogers RA, Austen KF, Arm JP. Low molecular weight group IIA and group V phospholipase A₂ enzymes have different intracellular locations in mouse bone marrow-derived mast cells. *J Biol Chem*, 1999; 274:31476-84.
7. Ho C-I, Arm JP, Bingham CO III, Choi A, Austen KF, Glimcher LH. A novel group of phospholipase A₂ preferentially expressed in Th2 cells. *J Biol Chem*, 2001; 276: 18321-6.
8. Kulig K, Bingham CO III, Steele LL. Racial, ethnic, and geographic disparities in total knee arthroplasty. *N Engl J Med* 2004; 350: 305-6.
9. Greenberg JD, Bingham CO III, Abramson SB, Reed G, Sebaldt RJ, Kremer J. Effects of cardiovascular comorbidities and concomitant aspirin use on selection of cyclooxygenase inhibitor among rheumatologists. *Arthritis Rheum* 2005; 53: 12-17.
10. Mor A, Bingham CO III, Barisono L, Lydon E, Belmont HM. Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. *J Rheumatol* 2005; 32:740-3.

Book Chapters, Review Articles:

1. Bingham CO III, Austen KF. The Molecular and Cellular Biology of the Mast Cell. In: Reedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, and Fitzpatrick TB, editors. *Dermatology in General Medicine 5th Edition*. New York: McGraw Hill, 1999; 414-22.
2. Bingham CO III, Arm JP, Austen KF. Arachidonic Acid Metabolism in Mast Cells. In: Razin E and Rivera JP, editors. *Signal Transduction in Mast Cells and Basophils*. New York: Springer-Verlag, 1999; 350-61.
3. Bingham CO III, Austen KF. Phospholipase A₂ Enzymes in Eicosanoid Generation. *Proc Assoc Am Physicians*, 1999; 111:516-24.
4. Bingham CO III, Austen KF. Mast Cell Responses in the Development of Asthma. *J Allergy Clin Immunol*, 2000; 105: 527-34.
5. Attur M, Bingham CO III, Dave M, Abramson SB, Amin AR. Model protocol to study pharmacogenomics in inflammatory diseases: Human rheumatoid arthritis. *Drug Development Research*, 2000; 49: 29-33.
6. Bingham CO III, Abramson SB. Mediators of Inflammation, tissue destruction, and repair: Cellular Constituents. *Primer on the Rheumatic Diseases (12th Edition)*. Klippel JH, Crofford LJ, Stone JH, Weyand CM. (Eds). Atlanta, GA: Arthritis Foundation, 2001:51-8.
7. Bingham CO III, Abramson SA. Mechanisms of Inflammation, *Mechanisms in Rheumatology*. Ed. Tannenbaum H., Russell AS, Core Health Services, Toronto 2001;Chapter 4: 29-39.
8. Bingham CO III. Development and clinical application of COX-2-selective inhibitors for the treatment of osteoarthritis and rheumatoid arthritis. *Cleveland Clinic Journal of Medicine*, 2002; 69: SI-1 – SI-8.
9. Bingham CO III. The pathogenesis of rheumatoid arthritis: pivotal cytokines involved in bone degradation and inflammation. *J Rheumatology*; 2002;29 Suppl 65:3-9.
10. Hsieh FH, Bingham CO III, Austen KF. The molecular and cellular biology of the mast cell. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, and Fitzpatrick TB, editors. *Dermatology in General Medicine 6th Edition*. New York: McGraw Hill; 2003; Chapter 32:330-5.
11. Imperato AK, Bingham CO III, Abramson SB. Overview of benefit/risk of biological agents. *Clin Exp Rheumatol*. 2004; 22: S108-14.
12. Reddy SM, Bingham III CO. Clinical Assessment of Psoriatic Arthritis. In KB Gordon and EM Ruderman, eds.: *Psoriasis and Psoriatic Arthritis: An Integrated Approach*. Springer-Verlag, Heidelberg. (in press)

C. Research Support

Ongoing Research Support

Arthritis Investigator Award Bingham (PI) 1/1/05-6/30/06
 Arthritis Foundation
 Oral Health in Subjects with Inflammatory Arthritis
 This is a study to perform a comprehensive evaluation of oral health in a cohort of patients with newly diagnosed inflammatory arthritis patients.

Investigator-Initiated Clinical Trial Bingham (PI) 3/1/05-3/1/06
 Genetech
 A Phase I/II Evaluation of the Safety and Efficacy of Rituximab for Chronic Autoimmune Urticaria
 Role: PI

Completed Research Support

Goldstein Young Investigator/ Arthritis Investigator Bingham (PI) 7/1/01-12/30/04
 Arthritis Foundation, NY Chapter/ National
 Evaluation of Low Molecular Weight Phospholipase A2 Expression in Synovial Tissue
 The purpose of this study is to examine synovial tissue from patients with different forms of arthritis for the expression of a family of PLA2 proteins.
 Role: PI

N01 AR92236 Clegg (PI) 9/15/00-12/30/04
 NIH/NIAMS
 Glucosamine Arthritis Intervention Trial (GAIT)
 This is a multicenter, randomized, placebo-controlled, parallel group study of glucosamine, chondroitin sulfate, and the combination in osteoarthritis of the knee using celecoxib as a comparator.
 Role: Site PI

R01 AR47206 Abramson (PI) 7/1/01-12/30/05
 NIH/NIAMS
 COX-2 Eicosanoids in Arthritis
 This study is an examination of eicosanoid biosynthetic pathway enzymes in osteoarthritis cartilage.
 Role: Co-investigator

Investigator-Initiated Study Bingham (PI) 8/1/03-12/30/04
 Amgen/Abbott
 DTH Responses and Tuberculosis Susceptibility in Patients with Rheumatoid Arthritis
 This study is to evaluate the prevalence of cutaneous anergy and to evaluate tuberculosis screening strategies in patients with rheumatoid arthritis.
 Role: PI

Multicenter Investigator-Initiated Clinical Trial Moreland (PI) 9/1/03-12/30/04
 Amgen
 Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)
 This is a study to investigate various treatment protocols including traditional DMARDs and biologic DMARDs for patients with early aggressive RA. This is an investigator-initiated, multicenter clinical trial, with funding from Amgen.
 Role: NYU Site PI

Industry-sponsored Registry Bingham (PI) 1/14/01-12/30/04
 Abbott
 Study of New Onset Rheumatoid Arthritis (SONORA), longitudinal registry
 Role: Site PI

Industry-sponsored Clinical Trial Bingham (PI) 9/13/99-10/1/03

Principal Investigator/Program Director (Last, First, Middle): **Bartlett, Susan**

Proctor and Gamble

Phase III Study of Risedronate as Structure Modifying Therapy in Patients with Osteoarthritis of the Knee

Role: Overall Study PI, Site PI

Industry-sponsored Clinical Trial

Bingham (PI)

8/14/02-8/13/03

Regeneron

Phase II Study of IL1-TRAP for RA

Role: Overall Study PI, Site PI

Pending Research Support

R03 AR051356

Bingham (PI)

12/01/05-11/30/07

NIH/NIAMS

Periodontal Assessment in Rheumatoid Arthritis Study (PARAS)

This is a collaborative study with the University of Maryland College of Dentistry to evaluate the prevalence of periodontal disease in a cohort of patients with newly diagnosed rheumatoid arthritis with longitudinal follow up evaluation and to explore shared mechanisms of disease pathogenesis.